- August 2021 |
- Healthcare & Pharmaceutical / Pharmaceuticals
Global Polycythemia Vera Drug Sales Market, By Type (Dasatinib, Idelalisib, Givinostat, M-009, and Others), By Application (Clinic, Hospital, Others), By Region (North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle-East & Africa (MEA) Trend Analysis, Competitive Market Share & Forecast, 2017-2027
Global Polycythemia Vera Drug Sales Market- Industry Trends & Forecast Report 2027
The global polycythemia vera drug sales market is growing at an impressive rate across the globe and is expected to witness significant progress in the foreseeable future. The rising risk associated with polycythemia vera and the growing public awareness regarding health and diseases, combined with developing healthcare infrastructure, and increasing disposable income of the masses are some of the primary factors contributing towards the growth of the global polycythemia vera drug sales market. Additionally, researchers are focusing on the development of novel treatments for combating polycythemia vera, which is expected to fuel the growth of the polycythemia vera drug industry.
Global Polycythemia Vera Drug Sales Market- Overview
Polycythemia vera is a very rare type of blood cancer that originates in the bone marrow. It triggers your bone marrow to produce an abnormally large number of red blood cells. These extra cells end up thickening the blood, restricting its circulation, and potentially causing severe problems including blood clots. Polycythemia is diagnosed when the hematocrit exceeds 48% and 52% in women and men, respectively. It also results in a high level of hemoglobin which becomes serious if it gets higher than 16.5g/DL in women and 18.5g/DL in men. The rising prevalence of Polycythemia vera cases is expected to propel the polycythemia vera treatment market forward.
Global Polycythemia Vera Drug Sales Market Forecast and Trends
The Increasing Dependence on Drug Therapy for Driving the Market Growth
The polycythemia vera disease is non-curable and can only be treated. Drug therapy or Phlebotomy are used in the treatment of polycythemia vera. While Phlebotomy is the elimination of blood from the body, Interferon-alfa and Hydroxyurea are used in drug therapy. Ruxolitinib (jakafi) or busulfan are used to treat patients who do not react to hydroxyurea.
Phlebotomy is a surgical operation in which a vein is opened or punctured to withdraw blood. This type of treatment entails a higher level of risk and is often more costly. Therefore, patients choose drug therapy over surgical operations. This induces the demand for global polycythemia vera drugs, which in turn propels the growth of the polycythemia vera disease sales market. Furthermore, since polycythemia vera drugs are more successful and provide better results, patients have a higher level of confidence in such drugs.